Physician profile
Mu Li
NPI 1518497940
$662.21
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $392 · 2020: $170 · 2023: $99.95.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $99.95 | 2023 | |
| Seagen INC. | $95.00 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $82.78 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $64.24 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $47.26 | 2019 | |
| Alexion Pharmaceuticals, INC. | $47.11 | 2019 | |
| Pfizer INC. | $42.18 | 2019-2020 | |
| Biogen, INC. | $41.48 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $30.32 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $23.03 | 2020 | |
| Abbvie INC. | $22.91 | 2019 | |
| Viiv Healthcare Company | $20.96 | 2019 | |
| Shire North American Group INC | $18.18 | 2019 | |
| Novartis Pharmaceuticals Corporation | $15.22 | 2019 | |
| Glaxosmithkline, LLC. | $11.59 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mu Li listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.